trending Market Intelligence /marketintelligence/en/news-insights/trending/ZXqg-IRk1UU1eB94YdbIWw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lexicon's Zynquista helps treat type 2 diabetes in late-stage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Lexicon's Zynquista helps treat type 2 diabetes in late-stage study

Lexicon Pharmaceuticals Inc.'s diabetes drug Zynquista beat placebo and matched Eli Lilly and Co.'s Jardiance in reducing blood sugar levels of certain patients with type 2 diabetes in a late-stage study.

The Sota-Empa multicenter study compared the effectiveness of Zynquista, placebo and empagliflozin, sold by Lilly and Boehringer Ingelheim GmbH under brand name Jardiance, on 700 patients over a 26 week period.

Patients in the study had inadequate sugar metabolism from type 2 diabetes, despite using a class of oral drugs known as Dipeptidyl peptidase-4 inhibitors, which help preserve a group of hormones that decrease glucose levels in the blood.

The company expects top-line results from its remaining late-stage studies of Zynquista in early 2020, Lexicon's executive vice president and chief medical officer, Pablo Lapuerta, said in a statement.

Zynquista, or sotagliflozin, was approved by the European Commission in April as an add-on therapy for adults with type 1 diabetes. In contrast, the U.S Food and Drug Administration rejected it for the same treatment and denied the Woodlands, Texas-based company's appeal over the rejection.